Suvorexant was the first selective dual orexin receptor antagonist (DORA) to be approved in recent times. It would bind reversibly with both the orexin receptors, OX1R and OX2R, and …

Suvorexant is a potent dual orexin receptor antagonist that blocks both OX1R and OX2R. It promotes sleep through the binding inhibition of orexin A and B, neuropeptides that promote …

Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication which is used in the treatment of insomnia. [2][6] It is indicated specifically for the treatment of insomnia …

Suvorexant, the first dual orexin receptor antagonist (DORA) to be approved for the treatment of insomnia, is a promising agent that offers a new option for patients seeking treatment for …

苏沃雷生（Suvorexant），品牌名Belsomra，是一种 食欲素受体拮抗剂 （ 英语 ： Orexin_antagonist ） ，被用于治疗失眠症，主要用于入睡或睡眠维持困难的成年患者的治疗。

2024年9月14日 · Dual orexin receptor antagonists (DORAs) have been investigated as a treatment for chronic insomnia. The objective of this systematic review was to examine …

Suvorexant is used treat insomnia (difficulty falling asleep or staying asleep). Suvorexant is in a class of medications called orexin receptor antagonists. It works by blocking the action of a …

A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists. Orexin receptors in the brain have been …

Suvorexant is the first dual orexin receptor antagonist approved for the treatment of insomnia. Clinical trials have shown that it is relatively safe and effective for the treatment of both sleep …

2015年6月14日 · Belsomra (suvorexant) is a first-in-class orexin receptor antagonist. It is a CNS depressant and blocks the binding of wake-promoting neuropeptides orexin A and orexin B to …